Novo Nordisk (NVO) said Friday its phase 3b trial comparing subcutaneous semaglutide 7.2 mg with semaglutide 2.4 mg and placebo achieved its primary endpoint by demonstrating a "statistically significant and superior" weight loss at week 72.
The trial, which involved 1,407 adults with obesity, showed participants administered with semaglutide 7.2 mg on a weekly basis alongside lifestyle interventions achieved a 20.7% weight loss from a mean baseline weight of 113 kg. This compares to a 17.5% reduction with semaglutide 2.4 mg and 2.4% with placebo.
The trial demonstrated that 33.2% of participants receiving semaglutide 7.2 mg achieved at least 25% weight loss, outperforming the 16.7% with semaglutide 2.4 mg and 0% with placebo.
Novo Nordisk said the semaglutide 7.2 mg demonstrated a safe and well-tolerated profile, with most adverse events being mild to moderate gastrointestinal issues that diminished over time.
Novo Nordisk shares were 2.5% lower in premarket trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。